To include your compound in the COVID-19 Resource Center, submit it here.

Sarepta's golodirsen under FDA Priority Review

Sarepta Therapeutics Inc. (NASDAQ:SRPT) said Feb. 14 that FDA accepted and granted Priority Review to its NDA

Read the full 171 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE